National Toxicology Program

National Toxicology Program
https://ntp.niehs.nih.gov/go/4388

TDMS Study 93026-06 Pathology Tables

NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40

                                                      Final#1, Revision#2




       Facility:  Battelle Northwest

       Chemical CAS #:  91-17-8

       Lock Date:  01/04/01

       Cage Range:  All

       Reasons For Removal:    25022 Accidently Killed                 25019 Moribund Sacrifice
                               25020 Natural Death                     25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include All

































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50                                     
  Early Deaths                                                                                                                      
    Natural Death                                      2            7            3            6                                     
    Moribund Sacrifice                                10           15           11            8                                     
    Accidently Killed                                                            1                                                  
  Survivors                                                                                                                         
    Moribund Sacrifice                                                                        1                                     
    Terminal Sacrifice                                37           28           35           35                                     
                                                                                                                                    
  Animals Examined Microscopically                    49           50           50           50                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Esophagus                                          (49)         (50)         (50)         (50)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
   Gallbladder                                        (41)         (40)         (40)         (38)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (3%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (3%)                                             
   Intestine Large, Cecum                             (48)         (43)         (47)         (46)                                   
      Leiomyoma                                        1 (2%)                                                                       
   Intestine Small, Duodenum                          (48)         (43)         (47)         (47)                                   
      Polyp Adenomatous                                                                       1 (2%)                                
   Intestine Small, Ileum                             (47)         (45)         (49)         (47)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
   Liver                                              (49)         (50)         (50)         (50)                                   
      Hemangiosarcoma                                                                         1 (2%)                                
      Hepatoblastoma                                                                          1 (2%)                                
      Hepatocellular Carcinoma                         4 (8%)      15 (30%)      6 (12%)      5 (10%)                               
      Hepatocellular Carcinoma, Multiple                            1 (2%)                                                          
      Hepatocellular Adenoma                           4 (8%)      11 (22%)      7 (14%)     14 (28%)                               
      Hepatocellular Adenoma, Multiple                 3 (6%)       2 (4%)       1 (2%)       3 (6%)                                
      Hepatocholangiocarcinoma                                      1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Sarcoma, Metastatic, Skin                                     1 (2%)                                                          
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Mesentery                                          (17)         (18)         (12)         (18)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (6%)                                                          
      Sarcoma, Metastatic, Skin                                     1 (6%)                                                          
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
   Pancreas                                           (49)         (47)         (50)         (49)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
   Salivary Glands                                    (49)         (50)         (50)         (50)                                   
   Stomach, Forestomach                               (49)         (49)         (50)         (47)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Squamous Cell Carcinoma                                       1 (2%)                    1 (2%)                                
   Stomach, Glandular                                 (48)         (47)         (50)         (47)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
   Tongue                                             (1)                                                                           
      Squamous Cell Carcinoma                          1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Blood Vessel                                                                 (2)                                                 
      Aorta, Mast Cell Tumor Malignant, Metastatic,                                                                                 
           Uncertain Primary Site                                                1 (50%)                                            
   Heart                                              (49)         (50)         (50)         (50)                                   
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (49)         (50)         (50)         (49)                                   
      Subcapsular, Adenoma                             1 (2%)                                                                       
   Adrenal Medulla                                    (48)         (50)         (50)         (49)                                   
      Pheochromocytoma Benign                          2 (4%)                    2 (4%)       1 (2%)                                
   Islets, Pancreatic                                 (49)         (47)         (50)         (49)                                   
      Adenoma                                          1 (2%)                    1 (2%)                                             
   Pituitary Gland                                    (49)         (49)         (49)         (50)                                   
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Pars Distalis, Adenoma                          13 (27%)      8 (16%)     10 (20%)     17 (34%)                               
      Pars Intermedia, Adenoma                         1 (2%)       1 (2%)       2 (4%)       2 (4%)                                
   Thyroid Gland                                      (49)         (49)         (50)         (47)                                   
      Follicular Cell, Adenoma                         1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (49)         (49)         (49)         (48)                                   
      Carcinoma, Metastatic, Uterus                                 1 (2%)                                                          
      Cystadenoma                                      1 (2%)                    3 (6%)       2 (4%)                                
      Granulosa Cell Tumor Malignant                                                          1 (2%)                                
      Granulosa Cell Tumor Benign                      1 (2%)                    1 (2%)       1 (2%)                                
      Granulosa-Theca Tumor Malignant                                            1 (2%)                                             
      Hemangioma                                       1 (2%)                                                                       
      Hemangiosarcoma                                                            1 (2%)                                             
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Luteoma                                          1 (2%)                                                                       
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Tubulostromal Adenoma                                                      1 (2%)                                             
   Uterus                                             (49)         (49)         (50)         (49)                                   
      Carcinoma                                        1 (2%)       1 (2%)                                                          
      Hemangiosarcoma                                               1 (2%)                    1 (2%)                                
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Polyp Stromal                                                              2 (4%)       3 (6%)                                
      Sarcoma Stromal                                                                         1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (49)         (50)         (50)         (48)                                   
      Hemangiosarcoma                                                            1 (2%)       1 (2%)                                
   Lymph Node                                         (5)          (2)          (4)          (1)                                    
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (25%)                                            
      Iliac, Mast Cell Tumor Malignant, Metastatic,                                                                                 
           Uncertain Primary Site                                                1 (25%)                                            
   Lymph Node, Bronchial                              (41)         (45)         (47)         (44)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - cont                                                                                                         
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Lymph Node, Mandibular                             (36)         (40)         (37)         (41)                                   
      Carcinoma, Metastatic, Harderian Gland                                     1 (3%)                                             
   Lymph Node, Mesenteric                             (47)         (47)         (50)         (47)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Lymph Node, Mediastinal                            (43)         (42)         (43)         (46)                                   
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                                                1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Spleen                                             (49)         (47)         (50)         (48)                                   
      Hemangiosarcoma                                  1 (2%)       1 (2%)       1 (2%)       2 (4%)                                
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
   Thymus                                             (48)         (48)         (48)         (47)                                   
      Thymoma Benign                                                                          1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (48)         (50)         (50)         (50)                                   
      Carcinoma                                        1 (2%)       2 (4%)       2 (4%)                                             
   Skin                                               (49)         (50)         (50)         (50)                                   
      Basal Cell Carcinoma                                          1 (2%)                                                          
      Mast Cell Tumor Benign                                                                  1 (2%)                                
      Neural Crest Tumor                                                         1 (2%)                                             
      Squamous Cell Papilloma                                                    1 (2%)                                             
      Subcutaneous Tissue, Fibrosarcoma                                          1 (2%)                                             
      Subcutaneous Tissue, Fibrous Histiocytoma                     1 (2%)                    1 (2%)                                
      Subcutaneous Tissue, Hemangiosarcoma                          1 (2%)                    1 (2%)                                
      Subcutaneous Tissue, Sarcoma                     2 (4%)       2 (4%)       2 (4%)       1 (2%)                                
      Subcutaneous Tissue, Schwannoma Malignant                                  1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (49)         (50)         (50)         (50)                                   
      Carcinoma, Metastatic, Uncertain Primary Site                              1 (2%)                                             
      Osteoma                                                       1 (2%)                                                          
   Skeletal Muscle                                                 (2)                                                              
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (50%)                                                         
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (49)         (50)         (50)         (50)                                   
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Larynx                                             (49)         (50)         (50)         (49)                                   
   Lung                                               (49)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Adenoma                     1 (2%)       4 (8%)                    4 (8%)                                
      Alveolar/Bronchiolar Carcinoma                   6 (12%)      3 (6%)       1 (2%)       1 (2%)                                
      Carcinoma, Metastatic, Harderian Gland                                     1 (2%)                                             
      Carcinoma, Metastatic, Uterus                                 1 (2%)                                                          
      Hemangiosarcoma, Metastatic, Liver                                                      1 (2%)                                
      Hemangiosarcoma, Metastatic, Skin                             1 (2%)                                                          
      Hepatocellular Carcinoma, Metastatic, Liver      2 (4%)       1 (2%)       2 (4%)                                             
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
      Mediastinum, Alveolar/Bronchiolar Carcinoma,                                                                                  
           Metastatic, Lung                            1 (2%)                                                                       
      Mediastinum, Sarcoma, Metastatic, Skin                        1 (2%)                                                          
   Nose                                               (49)         (50)         (50)         (49)                                   
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
   Pleura                                             (1)                                    (1)                                    
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (2)          (1)          (2)                                                 
      Carcinoma, Metastatic, Uncertain Primary Site                              1 (50%)                                            
   Harderian Gland                                    (4)          (4)          (5)          (3)                                    
      Adenoma                                          3 (75%)      4 (100%)     2 (40%)      2 (67%)                               
      Carcinoma                                        1 (25%)                   3 (60%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (49)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                        1 (2%)                                                                       
      Hepatocholangiocarcinoma, Metastatic, Liver                   1 (2%)                                                          
      Mast Cell Tumor Malignant, Metastatic,                                                                                        
          Uncertain Primary Site                                                 1 (2%)                                             
   Urinary Bladder                                    (49)         (46)         (49)         (47)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(49)        *(50)        *(50)        *(50)                                   
      Lymphoma Malignant                              11 (22%)      8 (16%)     13 (26%)     14 (28%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            39          40          42          41                                       
     Total Primary Neoplasms                           63          70          67          84                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 28          25          27          34                                       
     Total Benign Neoplasms                            35          31          33          52                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              22          28          28          26                                       
     Total Malignant Neoplasms                         28          39          33          32                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              3           5           5           3                                       
     Total Metastatic Neoplasm                          4          23          23           9                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                       2           2                                       
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                          1                                                   
     Total Uncertain Neoplasms                                                  1                                                   
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                 7            7            7            5                                     
    Natural Death                                      3            2            7           11                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                39           41           35           33                                     
    Moribund Sacrifice                                                                        1                                     
    Natural Death                                      1                         1                                                  
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Gallbladder                                        (42)         (40)         (41)         (40)                                   
   Intestine Large, Cecum                             (48)         (48)         (49)         (46)                                   
      Polyp Adenomatous                                1 (2%)                                                                       
   Intestine Small, Duodenum                          (47)         (48)         (47)         (43)                                   
      Carcinoma                                                                  1 (2%)                                             
   Intestine Small, Jejunum                           (46)         (48)         (47)         (43)                                   
      Carcinoma                                                     1 (2%)       1 (2%)                                             
   Liver                                              (50)         (50)         (50)         (50)                                   
      Cholangioma                                                   1 (2%)                                                          
      Hemangiosarcoma                                  1 (2%)       3 (6%)                    2 (4%)                                
      Hepatoblastoma                                                1 (2%)                    1 (2%)                                
      Hepatocellular Carcinoma                        10 (20%)      7 (14%)      8 (16%)     11 (22%)                               
      Hepatocellular Carcinoma, Multiple                                         2 (4%)                                             
      Hepatocellular Adenoma                          16 (32%)     16 (32%)      9 (18%)     17 (34%)                               
      Hepatocellular Adenoma, Multiple                 6 (12%)      6 (12%)      5 (10%)     10 (20%)                               
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Liposarcoma, Metastatic, Mesentery                                                      1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Mesentery                                          (14)         (11)         (10)         (15)                                   
      Liposarcoma                                                                             1 (7%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (7%)                                
   Pancreas                                           (49)         (50)         (50)         (49)                                   
      Liposarcoma, Metastatic, Mesentery                                                      1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             2 (4%)                                
   Salivary Glands                                    (50)         (50)         (50)         (49)                                   
   Stomach, Forestomach                               (49)         (50)         (49)         (50)                                   
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
   Stomach, Glandular                                 (49)         (49)         (48)         (48)                                   
      Liposarcoma, Metastatic, Mesentery                                                      1 (2%)                                
   Tooth                                              (23)         (26)         (22)         (21)                                   
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (5%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                                               1 (2%)                                
      Carcinoma, Metastatic, Uncertain Primary Site                                           1 (2%)                                
      Hemangiosarcoma                                  1 (2%)       1 (2%)                                                          
      Hemangiosarcoma, Metastatic, Liver                                                      1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (49)         (50)         (50)         (50)                                   
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
      Subcapsular, Adenoma                             2 (4%)       1 (2%)                    4 (8%)                                
   Adrenal Medulla                                    (49)         (50)         (50)         (50)                                   
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Islets, Pancreatic                                 (49)         (50)         (50)         (49)                                   
      Adenoma                                          1 (2%)                    2 (4%)       2 (4%)                                
   Pituitary Gland                                    (48)         (50)         (50)         (49)                                   
      Pars Distalis, Adenoma                           1 (2%)       1 (2%)                                                          
   Thyroid Gland                                      (48)         (48)         (49)         (49)                                   
      Follicular Cell, Carcinoma                                                 1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Peritoneum                                                                                (1)                                    
      Hemangiosarcoma, Metastatic, Liver                                                      1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Coagulating Gland                                  (1)                                                                           
      Adenoma                                          1 (100%)                                                                     
   Epididymis                                         (50)         (50)         (50)         (50)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Preputial Gland                                    (49)         (49)         (50)         (50)                                   
      Hemangiosarcoma                                                            2 (4%)                                             
   Prostate                                           (48)         (50)         (50)         (50)                                   
   Seminal Vesicle                                    (49)         (50)         (50)         (50)                                   
      Liposarcoma, Metastatic, Mesentery                                                      1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Testes                                             (50)         (50)         (50)         (50)                                   
      Interstitial Cell, Adenoma                                                              3 (6%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (49)         (50)         (50)         (48)                                   
      Hemangiosarcoma                                  1 (2%)                                                                       
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Lymph Node                                         (1)                       (3)          (1)                                    
   Lymph Node, Bronchial                              (42)         (36)         (40)         (41)                                   
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                                  1 (3%)       2 (5%)                                
      Liposarcoma, Metastatic, Mesentery                                                      1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             2 (5%)                                
   Lymph Node, Mandibular                             (31)         (36)         (32)         (22)                                   
      Carcinoma, Metastatic, Harderian Gland           1 (3%)                                                                       
      Liposarcoma, Metastatic, Mesentery                                                      1 (5%)                                
   Lymph Node, Mesenteric                             (49)         (48)         (50)         (47)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Liposarcoma, Metastatic, Mesentery                                                      1 (2%)                                
      Plasma Cell Tumor Malignant                                   1 (2%)                                                          
      Sarcoma, Metastatic, Uncertain Primary Site                                             2 (4%)                                
   Lymph Node, Mediastinal                            (41)         (36)         (42)         (35)                                   
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                                               1 (3%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             2 (6%)                                
   Spleen                                             (49)         (50)         (50)         (49)                                   
      Hemangiosarcoma                                               3 (6%)                    2 (4%)                                
   Thymus                                             (44)         (44)         (42)         (40)                                   
      Carcinoma, Metastatic, Uncertain Primary Site                                           1 (3%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (50)         (50)         (50)                                   
      Squamous Cell Papilloma                                       1 (2%)                                                          
      Subcutaneous Tissue, Hemangioma                                            1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                                                           (2)                                    
      Liposarcoma, Metastatic, Mesentery                                                      1 (50%)                               
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (50%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Larynx                                             (50)         (50)         (50)         (50)                                   
      Carcinoma, Metastatic, Thyroid Gland                                       1 (2%)                                             
   Lung                                               (50)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Adenoma                     6 (12%)      5 (10%)      4 (8%)       2 (4%)                                
      Alveolar/Bronchiolar Adenoma, Multiple           2 (4%)                                                                       
      Alveolar/Bronchiolar Carcinoma                   6 (12%)      7 (14%)      6 (12%)     12 (24%)                               
      Alveolar/Bronchiolar Carcinoma, Multiple         2 (4%)       1 (2%)                                                          
      Carcinoma, Metastatic, Harderian Gland           2 (4%)                                                                       
      Carcinoma, Metastatic, Thyroid Gland                                       1 (2%)                                             
      Carcinoma, Metastatic, Uncertain Primary Site                                           1 (2%)                                
      Hemangiosarcoma, Metastatic, Liver                                                      1 (2%)                                
      Hepatocellular Carcinoma, Metastatic, Liver      3 (6%)       1 (2%)       4 (8%)       5 (10%)                               
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Liposarcoma, Metastatic, Mesentery                                                      1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             2 (4%)                                
      Mediastinum, Alveolar/Bronchiolar Carcinoma,                                                                                  
           Metastatic, Lung                                                                   2 (4%)                                
   Pleura                                                                                    (1)                                    
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (100%)                              
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (9)          (5)          (5)          (5)                                    
      Adenoma                                          6 (67%)      2 (40%)      4 (80%)      2 (40%)                               
      Carcinoma                                        3 (33%)      1 (20%)      1 (20%)      1 (20%)                               
      Bilateral, Adenoma                                            2 (40%)                   1 (20%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (49)         (50)         (50)         (49)                                   
      Carcinoma, Metastatic, Uncertain Primary Site                                           1 (2%)                                
      Sarcoma, Metastatic, Uncertain Primary Site                                             1 (2%)                                
   Urinary Bladder                                    (49)         (50)         (49)         (49)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)                                   
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Lymphoma Malignant                               3 (6%)       3 (6%)       4 (8%)       4 (8%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  13                                                               
                                                                                                                                   
NTP Experiment-Test: 93026-06  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                              DECALIN                                          Date: 04/11/02  
Route: RESPIRATORY EXPOSURE WHOLE BODY                                                                            Time: 09:23:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          CONTROL      25 PPM       100 PPM      400 PPM                                   
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            43          39          37          42                                       
     Total Primary Neoplasms                           69          64          52          75                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 32          27          22          32                                       
     Total Benign Neoplasms                            42          35          25          41                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              23          20          23          23                                       
     Total Malignant Neoplasms                         27          29          27          34                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              5           1           6          10                                       
     Total Metastatic Neoplasm                          6           1           7          48                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                   2                                       
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  14                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------                                           
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.